BAG3 (BCL2-associated athanogene 3) interacts with MMP-2 to positively regulate invasion by ovarian carcinoma cells

Cancer Letters

Volumn 303, Issue 1, 2011, Pages 65-71

  Suzuki, Miwa ^a   Iwasaki, Masahiro ^a   Sugio, Asuka ^a   Hishiya, Akinori ^b   Tanaka, Ryoichi ^a,b   Endo, Toshiaki ^a   Takayama, Shinichi ^b   Saito, Tsuyoshi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b BOSTON BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

BAG3; Invasion; MMP2; Ovarian carcinoma

Indexed keywords

BCL2 ASSOCIATED ATHANOGENE 3; GELATINASE A; ONCOPROTEIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER STAGING; CELL MOTILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE-FREE SURVIVAL; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 79951857812     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.01.019     Document Type: Article

References (26)

1. Takayama S., Xie Z., Reed J.C. An evolutionarily conserved family of Hsp70/Hsc70 molecular chaperone regulators. J. Biol. Chem. 1999, 274:781-786.
2. Takayama S., Reed J.C. Molecular chaperone targeting and regulation by BAG family proteins. Nat. Cell Biol. 2001, 3:E237-E241.
3. Iwasaki M., Homma S., Hishiya A., Dolezal S.J., Reed J.C., Takayama S. BAG3 regulates motility and adhesion of epithelial cancer cells. Cancer Res. 2007, 67:10252-10259.
4. Bork P., Sudol M. The WW domain: a signaling site in dystrophin?. Trends Biochem. Sci. 1994, 19:531-533.
5. Einbond A., Sudol M. Towards prediction of cognate complexes between the WW domain and proline-rich ligands. FEBS Lett. 1996, 384:1-8.
6. Sudol M., Chen H.I., Bougeret C., Einbond A., Bork P. Characterization of novel protein-binding module-the WW domain. FEBS Lett. 1996, 365:198-202.
7. Doong H., Price J., Kim Y.S., Gasbarre C., Probst J., Liotta L.A., Balanchette J., Rizzo K., Kohn E. CAIR-1/BAG3 forms an EGF-regulated ternary complex with phospholipase C-γ and HSP70/Hsc70. Oncogene 2000, 19:4385-4395.
8. Wu X., Li H., Kang L., Li L., Wang W., Shan B. Activated matrix metalloproteinase-2 - a potential marker of prognosis for epithelial ovarian cancer. Gynecol. Oncol. 2002, 84:126-134.
9. Niedbala M.J., Crickard K., Bernacki R.J. In vitro degradation of extracellular matrix by human ovarian carcinoma cells. Clin. Exp. Metast. 1987, 5:181-197.
10. Afzal S., Lalani E.N., Foulkes W.D., Boyce B., Tickle S., Cardillo M.R., Barker T., Pignatelli M., Stamp G.W. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinoma and tumor cell lines. Lab. Invest. 1996, 2:406-421.
11. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell Biol. 1995, 7:728-735.
12. Périgny M., Bairati I., Harvey I., Beauchemin M., Harel F., Plante M., Têtu B. Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am. J. Clin. Pathol. 2008, 129:226-231.
13. Kuwashima Y., Uehara T., Kurosumi M., Kishi K., Shiromizu K., Matsuzawa M., Takayama S. Basement membrane status I undifferenciated carcinomas of the ovary: immunohystochemical distribution of type IV collagen and laminin. Eur. J. Gynecol. Oncol. 1995, 16:181-186.
14. Trudel D., Fradet Y., Meyer F., Harel F., Têtu B. Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res. 2003, 63:8511-8515.
15. Holschneider C.H., Berek J.S. Ovarian cancer: epidemiology, biology, and prognostic factors. Sem. Surg. Oncol. 2000, 19:3-10.
16. Homma S., Iwasaki M., Gelton G.D., Engvall E., Reed J.C., Takayama S. BAG3 deficiency results in fulminant myopathy and early lethality. Am. J. Pathol. 2006, 169:761-773.
17. Liao Q., Ozawa F., Friess H., Zimmermann A., Takayama S., Reed J.C., Kleeff J., Büche M.W. The anti-apoptotic protein BAG3 is overexpressed in pancreatic cancer and induced by heat stress in pancreatic cancer cell lines. FEBS Lett. 2001, 503:151-157.
18. Du Z.X., Meng X., Zhang H.Y., Guan Y., Wang H.Q. Caspase-dependent cleavage of BAG3 in proteasome inhibitors-induced apoptosis in thyroid cancer cells. Biochem. Biophys. Res. Commun. 2008, 369:894-898.
19. Liu P., Xu B., Li J., Lu H. BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis. FEBS Lett. 2009, 583:401-406.
20. Stetler-Stevenson W.G., Aznavoorian S., Liotta L.A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol. 1993, 9:541-573.
21. Nishikawa A., Iwasaki M., Akutagawa N., Manase K., Yamashita S., Endo T., Kudo R. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential. Gynecol. Oncol. 2000, 79:256-263.
22. DeryuginaI E.I., Luo G.X., Reisfeld R.A., Bourdon M.A., Strongin A. Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2. Anticancer Res. 1997, 17:3201-3210.
23. Chan J.K., Tian C., Monk B.J., Herzog T., Kapp D.S., Bell J., Young R.C. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a gynecologic oncology group study. Cancer 2008, 112:2202-2210.
24. Creasman W.T., Rutledge F. The prognostiic value of peritoneal cytology in gynecologic malignant disease. Am. J. Obstet. Gynecol. 1971, 110:773-781.
25. Zuna R.E., Behrens A. Peritoneal washing cytology in gynecologic cancers: long-term follow-up of 355 patients. J. Natl. Cancer Inst. 1996, 88:980-987.
26. Kenny H.A., Lengyel E. MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle 2009, 8:693-698.